Trial Profile
A Randomized, Double Blind, Single-dose, Three-period, Crossover Study to Investigate Pharmacokinetic, Safety and Tolerability of Fluticasone Furoate With Umeclidinium When Administered in Combination and as Monotherapies in Adult Healthy Volunteer Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium/fluticasone furoate (Primary) ; Fluticasone furoate; Umeclidinium
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GSK
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Dec 2012 New trial record